Broadfin Capital LLC maintained its position in shares of Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) during the fourth quarter, Holdings Channel reports. The firm owned 8,951,169 shares of the company’s stock at the end of the fourth quarter. Progenics Pharmaceuticals accounts for 8.6% of Broadfin Capital LLC’s holdings, making the stock its 2nd largest position. Broadfin Capital LLC owned approximately 12.78% of Progenics Pharmaceuticals worth $77,338,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. Two Sigma Securities LLC bought a new position in shares of Progenics Pharmaceuticals during the third quarter worth approximately $109,000. Westwood Management Corp IL bought a new position in shares of Progenics Pharmaceuticals during the third quarter worth approximately $127,000. Dynamic Technology Lab Private Ltd bought a new position in shares of Progenics Pharmaceuticals during the fourth quarter worth approximately $144,000. Emerald Acquisition Ltd. bought a new position in shares of Progenics Pharmaceuticals during the second quarter worth approximately $278,000. Finally, Pacad Investment Ltd. bought a new position in shares of Progenics Pharmaceuticals during the fourth quarter worth approximately $303,000. 85.95% of the stock is owned by institutional investors and hedge funds.

Institutional Ownership by Quarter for Progenics Pharmaceuticals (NASDAQ:PGNX)

Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) traded up 9.56% on Thursday, reaching $10.54. 4,773,783 shares of the company traded hands. The firm has a market cap of $738.34 million, a P/E ratio of 68.00 and a beta of 3.11. The stock has a 50-day moving average price of $9.11 and a 200-day moving average price of $7.45. Progenics Pharmaceuticals Inc. has a 52-week low of $3.80 and a 52-week high of $10.56.

This article was originally posted by Daily Political and is the property of of Daily Political. If you are reading this article on another site, it was copied illegally and republished in violation of United States & international trademark & copyright laws. The legal version of this article can be accessed at http://www.dailypolitical.com/2017/02/16/progenics-pharmaceuticals-inc-pgnx-stake-maintained-by-broadfin-capital-llc.html.

PGNX has been the subject of several recent research reports. Aegis initiated coverage on shares of Progenics Pharmaceuticals in a research report on Wednesday, October 26th. They issued a “buy” rating and a $11.00 price target for the company. Jefferies Group LLC reissued a “buy” rating and issued a $9.00 price target on shares of Progenics Pharmaceuticals in a research report on Tuesday, November 8th. Needham & Company LLC set a $11.00 price target on shares of Progenics Pharmaceuticals and gave the stock a “buy” rating in a research report on Sunday, December 18th. BTIG Research increased their price target on shares of Progenics Pharmaceuticals from $9.00 to $11.00 and gave the stock a “buy” rating in a research report on Wednesday, November 30th. Finally, Zacks Investment Research raised shares of Progenics Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, December 14th. Two analysts have rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company. Progenics Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $10.79.

In other news, major shareholder Healthcare Master Fun Broadfin sold 602,600 shares of Progenics Pharmaceuticals stock in a transaction dated Wednesday, February 15th. The shares were sold at an average price of $9.66, for a total value of $5,821,116.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 5.48% of the company’s stock.

Progenics Pharmaceuticals Company Profile

Progenics Pharmaceuticals, Inc is engaged in developing medicines and other products for targeting and treating cancer. The Company’s products in development include therapeutic agents designed to target cancer and imaging agents, which focuses on enabling clinicians and patients to accurately visualize and manage their diseases.

5 Day Chart for NASDAQ:PGNX

Want to see what other hedge funds are holding PGNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Progenics Pharmaceuticals Inc. (NASDAQ:PGNX).

Receive News & Ratings for Progenics Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progenics Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.